Clinical Trials Logo

Kidney Cancer clinical trials

View clinical trials related to Kidney Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 5

NCT ID: NCT00003181 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Start date: May 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy with interleukin-2 and GM-CSF may be a more effective treatment for kidney cancer. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2, vinblastine, and GM-CSF in treating patients with metastatic kidney cancer.

NCT ID: NCT00002847 Active, not recruiting - Kidney Cancer Clinical Trials

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.

NCT ID: NCT00002846 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2 in treating patients with metastatic or recurrent kidney cancer.

NCT ID: NCT00002589 Active, not recruiting - Kidney Cancer Clinical Trials

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Start date: July 1994
Phase: Phase 2
Study type: Interventional

RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body. PURPOSE: This phase II trial is studying how well lymphocyte therapy works in treating patients with stage III or stage IV kidney cancer.